# Ruoyi Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ruoyi-bio

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.asiflyerbio.com
- Total disclosed funding: $7.8M
- Latest round: Angel (Mar 28, 2022)
- Investors on record: 3

## About

Founded in 2018 and based in Shanghai, China, Shanghai Ruoyi Biotechnology Co., Ltd, traing as Ruoyi Bio, is a biotech company that focuses on the development of macromolecular drug delivery technologies. It is a biotechnology startup incubated by ShanghaiTech University. Jia Liu, the chairman, founder, and CSO of the company, graduated from the University of Maryland, College Park, and is also a researcher at the Institute of Immunochemistry, ShanghaiTech University. In March 2026, Ruoyi Bio raised a series A funding from Kunshan Guoke Venture Investment and Qiji Gongjin (Shanghai) Life Science Partnership (Limited Partnership).

Ruoyi Bio's main business is the research and development of macromolecular drug delivery technology and related products. The company has independently developed a zinc finger protein drug delivery technology platform and an insect cell-baculovirus production process platform. The core drug pipeline under development is recombinant botulinum toxin protein drugs and intracellular antibodies. The products can be used to treat tumors and infectious diseases.

The company generates revenue by providing macromolecular drug delivery technology and related products.

The Angel funds raised in this round will be primarily used for the construction of an AI design platform and an advanced manufacturing platform for recombinant protein drugs.

## Funding rounds

- Angel, Mar 28, 2022, $7.8M — YuanBio Venture, ALAN AMC, Shanghai Trace Investment Management Co., Ltd.

## Investors

- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Angel
- ALAN AMC (https://capitalatlas.ai/funds/alan-amc) — Angel
- Shanghai Trace Investment Management Co., Ltd. — Angel